Identification of Clinically Relevant T Cell Receptors for Personalized T Cell Therapy Using Combinatorial Algorithms

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2024 May 7

PMID 38714897

Authors

Remy Petremand

Johanna Chiffelle

Sara Bobisse

Marta A S Perez

Julien Schmidt

Marion Arnaud

David Barras

Maria Lozano-Rabella

Raphael Genolet

Christophe Sauvage

Damien Saugy

Alexandra Michel

Anne-Laure Huguenin-Bergenat

Charlotte Capt

Jonathan S Moore

Claudio De Vito

S Intidhar Labidi-Galy

Lana E Kandalaft

Denarda Dangaj Laniti

Michal Bassani-Sternberg

Giacomo Oliveira

Catherine J Wu

George Coukos

Vincent Zoete

Alexandre Harari

Affiliations

Soon will be listed here.

Abstract

A central challenge in developing personalized cancer cell immunotherapy is the identification of tumor-reactive T cell receptors (TCRs). By exploiting the distinct transcriptomic profile of tumor-reactive T cells relative to bystander cells, we build and benchmark TRTpred, an antigen-agnostic in silico predictor of tumor-reactive TCRs. We integrate TRTpred with an avidity predictor to derive a combinatorial algorithm of clinically relevant TCRs for personalized T cell therapy and benchmark it in patient-derived xenografts.

Citing Articles

Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.

Kuilman T, Schrikkema D, Gadiot J, Gomez-Eerland R, Bies L, Walker J Nat Commun. 2025; 16(1):649.

PMID: 39809767 PMC: 11733228. DOI: 10.1038/s41467-024-55420-6.

Engineered Cellular Therapies for the Treatment of Thoracic Cancers.

Erickson S, Manning B, Kumar A, Patel M Cancers (Basel). 2025; 17(1.

PMID: 39796666 PMC: 11718842. DOI: 10.3390/cancers17010035.

Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.

Lin P, Lin Y, Mai Z, Zheng Y, Zheng J, Zhou Z Theranostics. 2025; 15(1):300-323.

PMID: 39744228 PMC: 11667231. DOI: 10.7150/thno.104594.

Predicting Antigen-Specificities of Orphan T Cell Receptors from Cancer Patients with TCRpcDist.

Perez M, Chiffelle J, Bobisse S, Mayol-Rullan F, Bugnon M, Bragina M Adv Sci (Weinh). 2024; 11(40):e2405949.

PMID: 39159239 PMC: 11516110. DOI: 10.1002/advs.202405949.

References

Rosenberg S, Restifo N . Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348(6230):62-8. PMC: 6295668. DOI: 10.1126/science.aaa4967. View

Rohaan M, Borch T, van den Berg J, Met O, Kessels R, Geukes Foppen M . Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022; 387(23):2113-2125. DOI: 10.1056/NEJMoa2210233. View

Kverneland A, Chamberlain C, Holz Borch T, Nielsen M, Mork S, Kjeldsen J . Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. J Immunother Cancer. 2021; 9(10). PMC: 8491427. DOI: 10.1136/jitc-2021-003499. View

Baulu E, Gardet C, Chuvin N, Depil S . TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv. 2023; 9(7):eadf3700. PMC: 9931212. DOI: 10.1126/sciadv.adf3700. View

Shafer P, Kelly L, Hoyos V . Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol. 2022; 13:835762. PMC: 8928448. DOI: 10.3389/fimmu.2022.835762. View

Veatch J, Lee S, Shasha C, Singhi N, Szeto J, Moshiri A . Neoantigen-specific CD4 T cells in human melanoma have diverse differentiation states and correlate with CD8 T cell, macrophage, and B cell function. Cancer Cell. 2022; 40(4):393-409.e9. PMC: 9011147. DOI: 10.1016/j.ccell.2022.03.006. View

Caushi J, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue E . Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021; 596(7870):126-132. PMC: 8338555. DOI: 10.1038/s41586-021-03752-4. View

Zheng C, Fass J, Shih Y, Gunderson A, Sanjuan Silva N, Huang H . Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers. Cancer Cell. 2022; 40(4):410-423.e7. DOI: 10.1016/j.ccell.2022.03.005. View

Hanada K, Zhao C, Gil-Hoyos R, Gartner J, Chow-Parmer C, Lowery F . A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell. 2022; 40(5):479-493.e6. PMC: 9196205. DOI: 10.1016/j.ccell.2022.03.012. View

10.

He J, Xiong X, Yang H, Li D, Liu X, Li S . Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res. 2022; 32(6):530-542. PMC: 9160085. DOI: 10.1038/s41422-022-00627-9. View

11.

Oliveira G, Stromhaug K, Klaeger S, Kula T, Frederick D, Le P . Phenotype, specificity and avidity of antitumour CD8 T cells in melanoma. Nature. 2021; 596(7870):119-125. PMC: 9187974. DOI: 10.1038/s41586-021-03704-y. View

12.

Li H, van der Leun A, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi A . Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell. 2019; 176(4):775-789.e18. PMC: 7253294. DOI: 10.1016/j.cell.2018.11.043. View

13.

Schmidt J, Chiffelle J, Perez M, Magnin M, Bobisse S, Arnaud M . Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat Commun. 2023; 14(1):3188. PMC: 10244384. DOI: 10.1038/s41467-023-38946-z. View

14.

van der Leun A, Thommen D, Schumacher T . CD8 T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020; 20(4):218-232. PMC: 7115982. DOI: 10.1038/s41568-019-0235-4. View

15.

Bobisse S, Bianchi V, Tanyi J, Sarivalasis A, Missiaglia E, Petremand R . A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nat Cancer. 2023; 4(10):1410-1417. DOI: 10.1038/s43018-023-00623-x. View

16.

Arnaud M, Chiffelle J, Genolet R, Rodrigo B, Perez M, Huber F . Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nat Biotechnol. 2021; 40(5):656-660. PMC: 9110298. DOI: 10.1038/s41587-021-01072-6. View

17.

Duraiswamy J, Turrini R, Minasyan A, Barras D, Crespo I, Grimm A . Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer Cell. 2021; 39(12):1623-1642.e20. PMC: 8861565. DOI: 10.1016/j.ccell.2021.10.008. View

18.

Irvine D, Maus M, Mooney D, Wong W . The future of engineered immune cell therapies. Science. 2022; 378(6622):853-858. PMC: 9919886. DOI: 10.1126/science.abq6990. View

19.

Mou T, Deng W, Gu F, Pawitan Y, Vu T . Reproducibility of Methods to Detect Differentially Expressed Genes from Single-Cell RNA Sequencing. Front Genet. 2020; 10:1331. PMC: 6979262. DOI: 10.3389/fgene.2019.01331. View

20.

Soneson C, Robinson M . Bias, robustness and scalability in single-cell differential expression analysis. Nat Methods. 2018; 15(4):255-261. DOI: 10.1038/nmeth.4612. View